contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


diagonal-bio-ab-diagonal-bio-announces-pilot-test-of-lamplifyr-at-norwegian-university-of-life-sciences

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Diagonal Bio operates in the biotechnology industry. The company is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service and associated ancillary services are also offered. The largest operations take place in Sweden with headquarter in Lund.

Diagonal Bio

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify®, at the Norwegian University...

<div class="abstract">Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces the commencement of a six-month pilot test of its point-of-care diagnostic platform, LAMPlify®, at the Norwegian University of Life Sciences (NMBU) in Ås. The pilot, which will be conducted in collaboration with the Faculty of Veterinary Medicine and Biosciences, specifically the Department of Companion Animal Clinical Sciences, aims to evaluate the effectiveness and potential integration of LAMPlify® within the university's equine hospital.</div>The veterinary team at NMBU, led by Associate Professor Ingunn Risnes Hellings, will test LAMPlify® in their animal hospital laboratory. As a leading teaching and commercial hospital, the equine department treats horses from across Norway, and this pilot will explore the feasibility of adopting LAMPlify® as a vital tool for rapid, on-site diagnostics in their medicine department.The pilot test will provide crucial insights into whether LAMPlify® can meet the hospital's needs for efficient, point-of-care diagnostics, potentially transforming the way they manage and treat equine patients."We're excited to see the growing interest in Diagonal Bio beyond Sweden. With partnerships already established in Denmark, it's clear that the demand for fast, accurate diagnostics is spreading, and we are proud to support improved veterinary care internationally. Further, I see this collaboration with the Norwegian University of Life Sciences as a great opportunity to see how LAMPlify® can improve diagnostic speed and accuracy in a busy veterinary setting."- Karin Wehlin, CEO of Diagonal Bio AB (publ) This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 25, 2024, at 14:15 CET.For additional information about, please contact: Karin Wehlin, CEOPhone: +46 703 052488E-mail: kw@diagonalbio.com Certified AdviserSvensk Kapitalmarknadsgranskning ABE-mail: ca@skmg.se About Diagonal BioDiagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.

Diagonal Bio AB: Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!